Tommy Parraga Acosta, MD
Infectious Disease · Huntsville, ALNPI 1235513672
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by La Jolla Pharmaceutical Company at 40.4% of the total. That places this record below the midpoint for infectious disease clinicians in AL, where the typical reported total is $923.
Across 9 payments — averaging $68.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- La Jolla Pharmaceutical Company$248
- Gilead$222
- Merck$128
- Insmed, Inc.$16
What the payments were for
- Food & beverage$59797%
- Education$163%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| La Jolla Pharmaceutical Company | 2 | $248 |
| Gilead | 2 | $222 |
| Merck | 4 | $128 |
| Insmed, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$613 in reported general payments places this provider in the 40th percentile of 104 infectious disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 156 | $148,354 |
| ErtapenemErtapenem Sodium | 115 | $53,235 |
| DalvanceDalbavancin Hcl | 14 | $30,305 |
| Meropenem | 25 | $15,436 |
| Cefepime Hcl | 35 | $5,855 |
| CeftriaxoneCeftriaxone Sodium | 44 | $5,513 |
| Vancomycin Hcl | 18 | $2,108 |
| Cefazolin Sodium | 22 | $1,387 |
| Doxycycline Hyclate | 30 | $1,237 |
| Sodium Chloride0.9 % Sodium Chloride | 118 | $828 |
| Cephalexin | 20 | $553 |
| Levofloxacin | 23 | $163 |
| Dextrose In WaterDextrose 5 % In Water | 12 | $41 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Huntsville
- Ali HassounHuntsville$262K
- Scott ParkerHuntsville$11K
- Hafsa SiddiquiHuntsville$5K
- Andres Gutierrez OrdonezHuntsville$2K
- Richard SperaHuntsville$2K
- Jordan Micah PolisticoHuntsville$1K
- Ingrid RoigHuntsville$646
- John BaddleyBirmingham$113K
- Christina MuznyBirmingham$111K
- Carlos Reyes-SacinMontgomery$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.